BioSpace News Archive

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company has received further guidance from the U.S. Food and Drug Administration (FDA) regarding the clinical hold on its ReMEDy2 Phase 2/3 trial for the treatment of acute ischemic stroke (AIS).

Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced completion of enrollment in the Phase 1 OMEGA Clinical Study for patients with peanut allergy.

The global plasmid DNA manufacturing market size is expected to hit around USD 1.71 billion by 2030 and growing at a CAGR of 15.43% from 2022 to 2030.

VIDA Diagnostics, Inc. (VIDA), the leader in imaging intelligence, has partnered with Wellspring Capital-backed RAYUS Radiology, a leading national provider of advanced diagnostic and interventional radiology, to onboard more than 150 locations as clinical trial imaging sites

Kidney care provider Monogram Health and leading health and well-being company Humana Inc. have announced a new value-based care agreement for most Humana Medicare Advantage HMO and PPO plan members in four states who live with chronic kidney disease.

According to Latest Report Study, the global recombinant proteins market size is projected to hit around USD 5.33 billion by 2030 and growing at a CAGR of 12.82% from 2022 to 2030

Scientists at The Feinstein Institutes for Medical Research, supported by a $6.7 million award from the National Institutes of Health (NIH), will create a detailed map of the anatomy of the human vagus nerve – one of the largest and most critical nerves controlling organ functions like heart rate, breathing, digestion, metabolism and immunological responses.

Pressure BioSciences, Inc. today confirmed specific product rollout plans agreed in their wide-ranging partnership with science-driven skincare industry leader Dr. Denese SkinScience.

The global synthetic small molecule API market size was valued at USD 131.63 billion in 2021 and it is predicted to surpass around USD 217.85 billion by 2030 with a CAGR of 5.76% from 2022 to 2030.

Carisma Therapeutics Inc. today announced that the company will present at two healthcare industry conferences and one investor conference in the fourth quarter of 2022.